{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:17Z","timestamp":1747181117620,"version":"3.40.5"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anaplastic lymphoma kinase (ALK) fusion, an important oncogenic mutation, occurs in 3% to 7% of non-small cell lung cancer (NSCLC) cases, and EML4 is the most common partner gene. With the widespread application of next-generation sequencing (NGS), more gene breakpoint fusions have been discovered and functional fusion transcripts can provide targeted clinical benefits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnosis:<\/jats:title>\n            <jats:p>A 40-year-old woman was diagnosed with lung adenocarcinoma with brain metastases. A novel CLHC1\/RNT4 intergenic region, ALK (Exon20-29) (abundance 39.97%), was identified using lung puncture tissue by NGS analysis (Simceredx), and results of immunohistochemistry and fluorescence in situ hybridization confirmed ALK fusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>The patient was administered oral crizotinib (250\u200amg bid) combined with endostar (30\u200amg d1-7) for 12 cycles from June 18, 2020. The patient's condition was controlled, and the curative effect was evaluated as stable disease (SD). Unfortunately, brain magnetic resonance images showed multiple nodules in the left cerebellar hemisphere, and chest computed tomography showed no significant changes in the progression of the disease. Subsequently, alectinib (600\u200amg bid) was administered on April 1, 2021. Brain lesions were significantly reduced and partial remission (PR) was achieved. No significant changes were observed in the lung lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>ALK fusion is a risk factor for brain metastasis (BM) in patients with advanced non-small NSCLC patients. In our case, a novel CLHC1\/RNT4 intergenic region, ALK fusion, was identified for the first time in a lung adenocarcinoma patient with BM, who benefited from crizotinib and endostar sequential alectinib. Our case highlights the advantages of NGS for fusion detection and provides promising treatment options for NSCLC patients with BM harboring ALK fusions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029134","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T13:00:23Z","timestamp":1650546023000},"page":"e29134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1\/RNT4 intergenic region- ALK fusion"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-6137","authenticated-orcid":false,"given":"Huanling","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Oncology, Jimo District People's Hospital, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jimo District People's Hospital, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jimo District People's Hospital, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxue","family":"Qi","sequence":"additional","affiliation":[{"name":"The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Luo","sequence":"additional","affiliation":[{"name":"The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Li","sequence":"additional","affiliation":[{"name":"The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","article-title":"Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC","volume":"15","author":"Li","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1758835918789364","DOI":"10.1177\/1758835918789364","article-title":"Alectinib in the treatment of ALK-positiven on-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy","volume":"10","author":"Vaval\u00e0","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.15252\/emmm.201911099","article-title":"Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition","volume":"12","author":"Paliouras","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"(Suppl 8)","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2020.04.014","article-title":"Chr2 30297612-ALK, a novel intergenic fusion with exon18 of ALK, responds to crizotinib","volume":"21","author":"Chen","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2020.03.009","article-title":"A novel Linc00308\/D21S2088E intergenic region ALK fusion and its enduring clinical responses to crizotinib","volume":"15","author":"Zhang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.jtho.2019.04.012","article-title":"A novel intergenic region between CENPA and DPYSL5-ALK Exon 20 fusion variant responding to crizotinib treatment in a patient with lung adenocarcinoma","volume":"14","author":"Fei","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cam4.2706","article-title":"Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:04:11Z","timestamp":1746327851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029134"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":10,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029134","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"2022-02-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}